FindTrial
Sign In

PD:24-TT:14

3 trials

Sponsors

GlaxoSmithKline Biologicals

Conditions

Booster vaccination against Streptococcus pneumoniae and active immunization against measles, mumps, rubella and varicella diseases in children during the second year of life.Catch-up immunization against Streptococcus pneumoniae in children older than 7 months at the time of the first vaccination and subdivided according to the age: • 7 to 11 months of age. • 12 to 23 months of age. • 24 months to 5 years of age.Three dose primary vaccination of preterm infants between 8-16 weeks (56-118 days) of age at the time of first vaccination against Streptococcus pneumoniae.

Phase 3

A phase IIIb open study to assess the safety and immunogenicity of GlaxoSmithKline (GSK) Biologicals´ 10-valent pneumococcal conjugate vaccine when co-administered with DTPa-HBV-IPV/Hib (Infanrix hexa) vaccine in preterm infants as a 3-dose primary immunisation course during the first 6 months of life - 10PN-PD-DIT-015
Active, not recruitingEUCTR2006-002898-47-GR
GlaxoSmithKline BiologicalsThree dose primary vaccination of preterm infants between 8-16 weeks (56-118 days) of age at the time of first vaccination against Streptococcus pneumoniae.
Start: 2007-01-16Target: 300Updated: 2022-08-08

Unknown Phase

A phase IIIb open, controlled study to evaluate the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine when given as a catch-up immunization in children older than 7 months of age or given as a 3-dose primary immunization in children before 6 months of age. - 10PN-PD-DIT-013
Active, not recruitingEUCTR2006-001482-42-FI
GlaxoSmithKline BiologicalsCatch-up immunization against Streptococcus pneumoniae in children older than 7 months at the time of the first vaccination and subdivided according to the age: • 7 to 11 months of age. • 12 to 23 months of age. • 24 months to 5 years of age.
Start: 2006-07-07Target: 600Updated: 2012-03-19
A phase IIIa open, randomised, controlled study to assess the safety, reactogenicity and immunogenicity induced by a booster dose of GlaxoSmithKline (GSK) Biologicals 10-valent pneumococcal conjugate vaccine when co-administered with GSK Biologicals’ measles-mumps-rubella-varicella vaccine (MMRV) vaccine in children during their second year of life, previously vaccinated in infancy in the primary study 10PN-PD-DIT-001 (105553) with GSK Biologicals 10-valent pneumococcal conjugate vaccine. - 10PN-PD-DIT-022 BST: 001
Active, not recruitingEUCTR2006-001934-42-FI
GlaxoSmithKline BiologicalsBooster vaccination against Streptococcus pneumoniae and active immunization against measles, mumps, rubella and varicella diseases in children during the second year of life.
Start: 2006-07-26Target: 400Updated: 2012-03-19